DIAMYD MEDICAL AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.36 SEK | +1.61% |
|
+15.92% | +72.91% |
| Apr. 18 | Diamyd Medical Raises SEK57 Million in Rights Issue | MT |
| Apr. 12 | Recruitment Milestone Reaches in Diamyd® Phase 3 Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.
Calendar
2024-06-25
- Q3 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +72.91% | 105M | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +0.23% | 22.2B | |
| -16.53% | 21.23B | |
| -10.70% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- DMYD B Stock
- News Diamyd Medical AB
- Diamyd Medical : Taps Icon for Late-Stage Study of Diabetes Vaccine
